In vitro dissolution of uranium oxide by baboon alveolar macrophages.
In vitro cellular dissolution tests for insoluble forms of uranium oxide are technically difficult with conventional methodology using adherent alveolar macrophages. The limited number of cells per flask and the slow dissolution rate in a large volume of nutritive medium are obvious restricting factors. Macrophages in suspension cannot be substituted because they represent different and poorly reproducible functional subtypes with regard to activation and enzyme secretion. Preliminary results on the dissolution of uranium oxide using immobilized alveolar macrophages are promising because large numbers of highly functional macrophages can be cultured in a limited volume. Cells were obtained by bronchoalveolar lavages performed on baboons (Papio papio) and then immobilized after the phagocytosis of uranium octoxide (U3O8) particles in alginate beads linked with Ca2+. The dissolution rate expressed as percentage of initial uranium content in cells was 0.039 +/- 0.016%/day for particles with a count median geometric diameter of 3.84 microns(sigma g = 1.84). A 2-fold increase in the dissolution rate was observed when the same number of particles was immobilized without macrophages. These results, obtained in vitro, suggest that the U3O8 preparation investigated should be assigned to inhalation class Y as recommended by the International Commission on Radiological Protection. Future experiments are intended to clarify this preliminary work and to examine the dissolution characteristics of other particles such as uranium dioxide. It is recommended that the dissolution rate should be measured over an interval of 3 weeks, which is compatible with the survival time of immobilized cells in culture and may reveal transformation states occurring with aging of the particles.
Poncy
J L
JL
CEA/DSV/DPTE/LRT, BP12-F-91680 Bruyeres le Chatel, France.
Metivier
H
H
Dhilly
M
M
Verry
M
M
Masse
R
R
D000818:Animals; D005260:Female; D016676:Macrophages, Alveolar / Q000378:metabolism*; D008297:Male; D010215:Papio; D010587:Phagocytosis; D012995:Solubility; D014501:Uranium / Q000493:pharmacokinetics*; D017974:Uranium Compounds
D017974:Uranium Compounds; D014501:Uranium; C047385:uranium oxide